Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Harrington Investments INC

Harrington Investments INC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 10.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 14,320 shares of the medical equipment provider’s stock after acquiring an additional 1,307 shares during the period. Harrington Investments INC’s holdings in Hologic were worth $1,032,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter valued at approximately $26,000. Groupama Asset Managment grew its stake in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its holdings in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 260 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 0.0 %

HOLX opened at $60.71 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 1 year low of $60.33 and a 1 year high of $84.67. The firm has a 50 day moving average price of $67.18 and a 200 day moving average price of $74.71. The company has a market cap of $13.62 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Royal Bank of Canada decreased their price objective on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Raymond James restated an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Hologic presently has an average rating of “Hold” and an average price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.